NCCN Receives Major Grant for Anti-Cancer Drug Study

JENKINTOWN, Pa., November 15, 2007 — The National Comprehensive Cancer Network (NCCN), ImClone Systems Incorporated and Bristol-Myers Squibb have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in head and neck cancer using cetuximab. Fox Chase Cancer Center (FCCC) in Philadelphia, Pennsylvania is the coordinating center for this study, with Corey Langer, M.D., serving as Project Chairman. Cetuximab, also known by its brand name ERBITUX®, is current...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news